NCT01675973View on ClinicalTrials.gov

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

PHASE1TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions

Severe Renal Impairment

Interventions

DRUG

RANEXA

500mg BID up to 1000mg BID

Trial Locations (1)

33014

Clinical Pharmacology of Miami, Miami

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY